Atopic dermatitis medical therapy
Atopic dermatitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Atopic dermatitis medical therapy On the Web |
American Roentgen Ray Society Images of Atopic dermatitis medical therapy |
Risk calculators and risk factors forAtopic dermatitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shalinder Singh, M.B.B.S.[2]
Overview
The mainstay of treatment for atopic dermatitis depends upon the severity of the disease. The treatment involves a combination of conservative and medical therapy. The goals of treatment include elimination of aggravating factors, skin barrier function repair, maintaining skin hydration and pharmacologic treatment of skin inflammation. Pharmacologic medical therapies for atopic dermatitis can be classified according to the several severity scales including SCORAD index, the eczema area and severity index (EASI) and the patient-oriented eczema measure (POEM).
Conservative Therapy
Elimination of exacerbating factors | Maintaining skin hydration | Controlling pruritus |
---|---|---|
|
|
|
Medical Therapy
- Pharmacologic medical therapies for atopic dermatitis can be classified according to the several severity scales including SCORAD index, the eczema area and severity index (EASI) and the patient-oriented eczema measure (POEM) which includes characteristics of the rash, questions about itch, sleep, impact on daily activities, and persistence of disease.[3]
Atopic dermatitis
- 1. Mild atopic dermatitis:
- 1.1 Topical corticosteroids and emollients - mainstay therapy
- 1.1.1 Adult
- Preferred regimen (1): Desonide 0.05% top. q12h-q24h for 14-28 days
- Preferred regimen (2): Hydrocortisone 2.5% top. q12h-q24h for 14-28 days[5]
- Preferred regimen (3): Fluocinolone acetonide 0.01% top. q12h-q24h for 14-28 days
- Alternative regimen (1): Tacrolimus 0.1% top. q12h (0.03% for adults who do not tolerate the higher dose)[6]
- Alternative regimen (2): Pimecrolimus 1% top. q12h[7]
- Alternative regimen (3) Crisaborole 2% top.[3]
- 1.1.2 Pediatric
- Preferred regimen (1): Desonide 0.05% top. q12h-q24h for 14-28 days
- Preferred regimen (2): Hydrocortisone 2.5% top. q12h-q24h for 14-28 days[8]
- Preferred regimen (3): Fluocinolone acetonide 0.01% top. q12h-q24h for 14-28 days
- Alternative regimen (1): Tacrolimus 0.03% top. q12h (Children (>2years)[9]
- Alternative regimen (2): Pimecrolimus 1% top. q12h[10]
- Alternative regimen (3): Crisaborole 2% top.
- 1.1.1 Adult
- 1.1 Topical corticosteroids and emollients - mainstay therapy
- 2 Moderate atopic dermatitis
- 2.1 Topical corticosteroids and emollients - mainstay therapy
- 2.1.1 Adult
- Preferred regimen (1): Fluocinolone 0.025%. q12h-q24h for 14-28 days
- Preferred regimen (2): Triamcinolone 0.1% top. q12h-q24h for 14-28 days
- Preferred regimen (3): Fluocinolone acetonide 0.025% top. q12h-q24h for 14-28 days
- Alternative regimen (1): Tacrolimus 0.1% top. q12h (0.03% for adults who do not tolerate the higher dose)[11]
- Alternative regimen (2): Pimecrolimus 1% top. q12h[12]
- Alternative regimen (3): crisaborole 2% top.
- 2.1.2 Pediatric
- Preferred regimen (1): Fluocinolone 0.025%. q12h-q24h for 14 days
- Preferred regimen (2): Triamcinolone 0.1% top. q12h-q24h for 14 days
- Preferred regimen (3): Fluocinolone acetonide 0.025% top. q12h-q24h for 14-28 days
- Alternative regimen (1): Tacrolimus 0.03% top. q12h (Children (>2years)[13]
- Alternative regimen (2): Pimecrolimus 1% top. q12h[14]
- Alternative regimen (3): crisaborole 2% top.
- 2.1.1 Adult
- 2.1 Topical corticosteroids and emollients - mainstay therapy
- 3. Severe atopic dermatitis
- 3.1 Phototherapy or systemic immunosuppressant treatment - mainstay therapy
- 3.1.1 Adult
- Preferred regimen (1): Phototherapy (Ultraviolet light therapy) with PUVA (psoralens plus ultraviolet A radiation), 3 times a week
- Preferred regimen (2): Cyclosporine PO 3-5 mg/kg o.d. for 6 weeks (monitor BP and serum creatinine q2 weeks for three months, f/u q month)[15]
- Alternative regimen (1): Methotrexate PO[16]
- Alternative regimen (2): Azathioprine PO[17]
- Alternative regimen (3): Mycophenolate mofetil PO
- Alternative regimen (4): Dupilumab 600 mg SQ once and then 300 mg SQ every 2 weeks thereafter[18]
- 3.1.2 Pediatric
- Preferred regimen (1): Phototherapy (Ultraviolet light therapy) with PUVA ( psoralens plus ultraviolet A radiation), 3 times a week(older children > 6 years)
- Alternative regimen (1): Cyclosporine PO 3 to 5 mg/kg per day o.d. for 6 weeks (monitor blood pressure and serum creatinine every 2 weeks for three months, f/b every month)[19][3]
- Alternative regimen (2): Azathioprine PO[20]
- Alternative regimen (3): Mycophenolate mofetil PO
- Alternative regimen (4): Dupilumab 600 mg SQ once and then 300 mg SQ every 2 weeks thereafter[21]
- 3.1.1 Adult
- 3.1 Phototherapy or systemic immunosuppressant treatment - mainstay therapy
- 4. Severe refractory atopic dermatitis
- 4.1 Adult
- Preferred regimen (1): Intensive topical therapy
- Soak and smear: Soak for 15 minutes in a tub of water. Apply desoximetasone 0.25% top. to the whole body, except the groin, axillae, and face.
- Wet wrap therapy: Desoximetasone 0.25% top. then occluded with wet wraps q12h
- Alternative regimen (1): Phototherapy: narrowband ultraviolet B or psoralen plus ultraviolet A two to three times per week
- Alternative regimen (2): Cyclosporine PO 2.5 to 5 mg/kg o.d. (C/I - abnormal renal function, uncontrolled hypertension or infection, and malignancy)[22]
- Alternative regimen (3): Prednisone 40 to 60 mg o.d. for one week, then taper the dose over the following two to three week
- Alternative regimen (4): Methotrexate 7.5 to 25 mg single weekly dose with folic acid 1 mg o.d.[23]
- Alternative regimen (5): Azathioprine 2 to 3 mg/kg[24]
- Alternative regimen (6): Mycophenolate mofetil 1 to 2 g/day
- Alternative regimen (7): Mycophenolic acid 720 to 1440 mg/day
- Alternative regimen (8): Dupilumab 600 mg SQ once and then 300 mg SQ every 2 weeks thereafter[25]
- Preferred regimen (1): Intensive topical therapy
- 4.2 Pediatric
- Preferred regimen (1): Intensive topical therapy
- Wet wrap therapy: Desoximetasone 0.05% top. then occluded with wet wraps q12h-q24h for 2 to 14 days
- Alternative regimen (1) Phototherapy: narrowband ultraviolet B (UVB) 3 times per week (older children > 6 years)[3]
- Alternative regimen (2): Cyclosporine PO 2.5 to 5 mg/kg o.d. for 2-4 months (monitor renal and hepatic function)[26]
- Alternative regimen (3): Methotrexate 0.5 mg/kg PO single weekly dose with folic acid 1 mg o.d.(up to a maximum of 25 mg per week)[27]
- Alternative regimen (4): Methylprednisolone 0.5 mg/kg o.d. for 1-2 weeks tapered over one month
- Preferred regimen (1): Intensive topical therapy
- 4.1 Adult
Other Drugs for atopic dermatitis:
- Interferon-γ sub-q o.d. for 12 weeks[28]
- Anti-CD20 therapy
- Anti-IgE
- Anti-TNFα therapy
- Anti-IL-6 receptor therapy
Adjuvant treatment:
- Primrose oil[33]
- Omega-3[34]
- Probiotics[35]
- Chinese herbal medicines
- Oral vitamin D[36]
Management of Infections:
- Bacterial infections: (most common bacteria - Staphylococcus aureus)[37]
- Clinically infected skin:
- Mupirocin 2% top. BID for one to two weeks
- More extensive infection: Oral antibiotic therapy with cephalosporins or penicillinase-resistant penicillins for two weeks.
- Clinically uninfected skin:
- Liquid chlorine bleach- 0.5 cup or 120 ml of 6% bleach in a full bathtub [40 gallons or 150 L] of lukewarm water[38]
- Clinically infected skin:
- Viral infections:
- Herpes simplex virus:
- Acyclovir 200 or 400 mg PO five times daily
- Famciclovir 750 mg BID for one day or 1500 mg as a single dose
- Molluscum contagiosum :
- Cryotherapy, curettage, cantharidin, and podophyllotoxin as first-line therapeutic options.
- Herpes simplex virus:
- Fungal infections:
- Dermatophyte infections - topical or oral antifungals[39]
Controlling pruritus:
- Preferred regimen:
- Sedatives: Diphenhydramine, hydroxyzine, and cyproheptadine
- Nonsedatives: Fexofenadine, cetirizine or loratadine
- Alternative regimen:
- Topical doxepin
- Topical calcineurin inhibitors
- Pimecrolimus 1% cream or tacrolimus 0.03% to 0.1%[13][14]
References
- ↑ Krakowski AC, Eichenfield LF, Dohil MA (October 2008). "Management of atopic dermatitis in the pediatric population". Pediatrics. 122 (4): 812–24. doi:10.1542/peds.2007-2232. PMID 18829806.
- ↑ Krakowski AC, Eichenfield LF, Dohil MA (October 2008). "Management of atopic dermatitis in the pediatric population". Pediatrics. 122 (4): 812–24. doi:10.1542/peds.2007-2232. PMID 18829806.
- ↑ 3.0 3.1 3.2 3.3 3.4 Ständer, Sonja; Ropper, Allan H. (2021). "Atopic Dermatitis". New England Journal of Medicine. 384 (12): 1136–1143. doi:10.1056/NEJMra2023911. ISSN 0028-4793.
- ↑ Krakowski AC, Eichenfield LF, Dohil MA (October 2008). "Management of atopic dermatitis in the pediatric population". Pediatrics. 122 (4): 812–24. doi:10.1542/peds.2007-2232. PMID 18829806.
- ↑ Aalto-Korte K, Turpeinen M (August 1995). "Pharmacokinetics of topical hydrocortisone at plasma level after applications once or twice daily in patients with widespread dermatitis". Br. J. Dermatol. 133 (2): 259–63. PMID 7547394.
- ↑ Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S (September 1997). "A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group". N. Engl. J. Med. 337 (12): 816–21. doi:10.1056/NEJM199709183371203. PMID 9295241.
- ↑ Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S (September 1997). "A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group". N. Engl. J. Med. 337 (12): 816–21. doi:10.1056/NEJM199709183371203. PMID 9295241.
- ↑ Aalto-Korte K, Turpeinen M (August 1995). "Pharmacokinetics of topical hydrocortisone at plasma level after applications once or twice daily in patients with widespread dermatitis". Br. J. Dermatol. 133 (2): 259–63. PMID 7547394.
- ↑ Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S (September 1997). "A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group". N. Engl. J. Med. 337 (12): 816–21. doi:10.1056/NEJM199709183371203. PMID 9295241.
- ↑ Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S (September 1997). "A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group". N. Engl. J. Med. 337 (12): 816–21. doi:10.1056/NEJM199709183371203. PMID 9295241.
- ↑ Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S (September 1997). "A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group". N. Engl. J. Med. 337 (12): 816–21. doi:10.1056/NEJM199709183371203. PMID 9295241.
- ↑ Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S (September 1997). "A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group". N. Engl. J. Med. 337 (12): 816–21. doi:10.1056/NEJM199709183371203. PMID 9295241.
- ↑ 13.0 13.1 Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S (September 1997). "A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group". N. Engl. J. Med. 337 (12): 816–21. doi:10.1056/NEJM199709183371203. PMID 9295241.
- ↑ 14.0 14.1 Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, Jablonska S, Ahmed I, Thestrup-Pedersen K, Daniel F, Finzi A, Reitamo S (September 1997). "A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group". N. Engl. J. Med. 337 (12): 816–21. doi:10.1056/NEJM199709183371203. PMID 9295241.
- ↑ Czech W, Bräutigam M, Weidinger G, Schöpf E (April 2000). "A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life". J. Am. Acad. Dermatol. 42 (4): 653–9. PMID 10727313.
- ↑ Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, Shpiro D, Trau H (January 2010). "Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults". J Eur Acad Dermatol Venereol. 24 (1): 43–9. doi:10.1111/j.1468-3083.2009.03351.x. PMID 19552716.
- ↑ Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, Hotchkiss K, Graham-Brown RA (August 2002). "Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial". Br. J. Dermatol. 147 (2): 324–30. PMID 12174106.
- ↑ Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR (July 2014). "Dupilumab treatment in adults with moderate-to-severe atopic dermatitis". N. Engl. J. Med. 371 (2): 130–9. doi:10.1056/NEJMoa1314768. PMID 25006719.
- ↑ Czech W, Bräutigam M, Weidinger G, Schöpf E (April 2000). "A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life". J. Am. Acad. Dermatol. 42 (4): 653–9. PMID 10727313.
- ↑ Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, Hotchkiss K, Graham-Brown RA (August 2002). "Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial". Br. J. Dermatol. 147 (2): 324–30. PMID 12174106.
- ↑ Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR (July 2014). "Dupilumab treatment in adults with moderate-to-severe atopic dermatitis". N. Engl. J. Med. 371 (2): 130–9. doi:10.1056/NEJMoa1314768. PMID 25006719.
- ↑ Czech W, Bräutigam M, Weidinger G, Schöpf E (April 2000). "A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life". J. Am. Acad. Dermatol. 42 (4): 653–9. PMID 10727313.
- ↑ Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, Shpiro D, Trau H (January 2010). "Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults". J Eur Acad Dermatol Venereol. 24 (1): 43–9. doi:10.1111/j.1468-3083.2009.03351.x. PMID 19552716.
- ↑ Berth-Jones J, Takwale A, Tan E, Barclay G, Agarwal S, Ahmed I, Hotchkiss K, Graham-Brown RA (August 2002). "Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial". Br. J. Dermatol. 147 (2): 324–30. PMID 12174106.
- ↑ Beck LA, Thaçi D, Hamilton JD, Graham NM, Bieber T, Rocklin R, Ming JE, Ren H, Kao R, Simpson E, Ardeleanu M, Weinstein SP, Pirozzi G, Guttman-Yassky E, Suárez-Fariñas M, Hager MD, Stahl N, Yancopoulos GD, Radin AR (July 2014). "Dupilumab treatment in adults with moderate-to-severe atopic dermatitis". N. Engl. J. Med. 371 (2): 130–9. doi:10.1056/NEJMoa1314768. PMID 25006719.
- ↑ Czech W, Bräutigam M, Weidinger G, Schöpf E (April 2000). "A body-weight-independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life". J. Am. Acad. Dermatol. 42 (4): 653–9. PMID 10727313.
- ↑ Lyakhovitsky A, Barzilai A, Heyman R, Baum S, Amichai B, Solomon M, Shpiro D, Trau H (January 2010). "Low-dose methotrexate treatment for moderate-to-severe atopic dermatitis in adults". J Eur Acad Dermatol Venereol. 24 (1): 43–9. doi:10.1111/j.1468-3083.2009.03351.x. PMID 19552716.
- ↑ Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte SJ, Cantu-Gonzales G (February 1993). "Recombinant interferon gamma therapy for atopic dermatitis". J. Am. Acad. Dermatol. 28 (2 Pt 1): 189–97. PMID 8432915.
- ↑ Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU (January 2008). "Anti-CD20 (rituximab) treatment improves atopic eczema". J. Allergy Clin. Immunol. 121 (1): 122–8. doi:10.1016/j.jaci.2007.11.016. PMID 18206507.
- ↑ Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ (January 2006). "Treatment of recalcitrant atopic dermatitis with omalizumab". J. Am. Acad. Dermatol. 54 (1): 68–72. doi:10.1016/j.jaad.2005.09.030. PMID 16384758.
- ↑ Jacobi A, Antoni C, Manger B, Schuler G, Hertl M (March 2005). "Infliximab in the treatment of moderate to severe atopic dermatitis". J. Am. Acad. Dermatol. 52 (3 Pt 1): 522–6. doi:10.1016/j.jaad.2004.11.022. PMID 15761436.
- ↑ Navarini AA, French LE, Hofbauer GF (November 2011). "Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection". J. Allergy Clin. Immunol. 128 (5): 1128–30. doi:10.1016/j.jaci.2011.09.009. PMID 21962991.
- ↑ Bamford JT, Ray S, Musekiwa A, van Gool C, Humphreys R, Ernst E (April 2013). "Oral evening primrose oil and borage oil for eczema". Cochrane Database Syst Rev (4): CD004416. doi:10.1002/14651858.CD004416.pub2. PMID 23633319.
- ↑ Koch C, Dölle S, Metzger M, Rasche C, Jungclas H, Rühl R, Renz H, Worm M (April 2008). "Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial". Br. J. Dermatol. 158 (4): 786–92. doi:10.1111/j.1365-2133.2007.08430.x. PMID 18241260.
- ↑ Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC (February 2012). "Dietary supplements for established atopic eczema". Cochrane Database Syst Rev (2): CD005205. doi:10.1002/14651858.CD005205.pub3. PMID 22336810.
- ↑ Peroni DG, Piacentini GL, Cametti E, Chinellato I, Boner AL (May 2011). "Correlation between serum 25-hydroxyvitamin D levels and severity of atopic dermatitis in children". Br. J. Dermatol. 164 (5): 1078–82. doi:10.1111/j.1365-2133.2010.10147.x. PMID 21087229.
- ↑ Ong PY, Leung DY (August 2010). "The infectious aspects of atopic dermatitis". Immunol Allergy Clin North Am. 30 (3): 309–21. doi:10.1016/j.iac.2010.05.001. PMC 2913147. PMID 20670815.
- ↑ Huang JT, Abrams M, Tlougan B, Rademaker A, Paller AS (May 2009). "Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity". Pediatrics. 123 (5): e808–14. doi:10.1542/peds.2008-2217. PMID 19403473.
- ↑ Lintu P, Savolainen J, Kortekangas-Savolainen O, Kalimo K (June 2001). "Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts". Allergy. 56 (6): 512–7. PMID 11421895.